Sirna Therapeutics Granted Two UK Patents on its RNAi Technology

The UK Patent Office has granted two patents to Sirna Therapeutics on the company's RNA interference technology.

The first patent covers the chemical and structural modifications of short interfering RNAs (siRNAs) needed for the creation of viable siRNA based therapeutics. The modifications covered in the patent are needed for the stability, potency and duration of action of siRNA therapeutics.

The second patent covers chemically modified siRNAs targeting a vascular endothelial growth factor receptor. The claims in the patent broadly cover any siRNA used against the entire targeted gene.